COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Phase I Open Label Dose Escalation Trial of RNA-144101 in the Treatment of Geographic Atrophy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01093170
Recruitment Status : Withdrawn (Study was not conducted, no subjects recruited.)
First Posted : March 25, 2010
Last Update Posted : January 17, 2018
Information provided by (Responsible Party):
Mark Kleinman, University of Kentucky

Brief Summary:
This is a non-randomized, open-label, dose-escalating Phase Ia study performed at a single center designed to evaluate the safety, pharmacokinetics, and preliminary efficacy of intravitreous administration of RNA-144101 in patients with geographic atrophy (GA).

Condition or disease Intervention/treatment Phase
Geographic Atrophy Drug: RNA-144101 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Open Label Dose Escalation Trial of RNA-144101 in the Treatment of Geographic Atrophy
Study Start Date : March 2011
Actual Primary Completion Date : September 2012
Actual Study Completion Date : September 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: RNA-144101 Drug: RNA-144101
Intravitreous administration of RNA-144101

Primary Outcome Measures :
  1. Safety and tolerability of RNA-144101 as measured by vision testing, ophthalmic and physical exams, vital signs, clinical laboratory testing and AEs. [ Time Frame: Through study completion or discontinuation ]

Secondary Outcome Measures :
  1. Pharmacokinetic studies measuring drug concentrations in serum over study period. [ Time Frame: Through study completion or discontinuation ]
  2. Measurement of total aggregate area of GA lesions (as determined by color fundus photography and autofluorescence imaging) [ Time Frame: Through duration of study or discontinuation ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males and females of all races and ethnicities between the ages of 50-99
  • Female subjects must be 1-year postmenopausal or surgically sterilized and must have negative serum pregnancy test
  • Subjects must have GA from AMD in one or both eyes:
  • The study eye will be the eye that meets all inclusion/exclusion criteria
  • If both eyes meet criteria, then the eye with the smaller GA lesion will be studied
  • If the GA lesions are equal in size, then the eye with the best-corrected visual acuity (BCVA) will chosen as the study eye
  • If both eyes have the same lesion size and same BCVA, the right eye will be chosen
  • Subjects must have the following GA criteria for inclusion:
  • GA lesions with an area > 2.5mm2 and ≤ 20mm2 as determine by fluorescein angiography and fundus autofluorescence
  • A clear view to the fundus must be present in order to easily examine the study eye at baseline
  • BCVA In the study eye between 20/20 and 20/100 as measured on Snellen chart or 85-50 letters by ETDRS
  • Willing and able to provide signed informed consent prior to any study participation

Exclusion Criteria:

  • GA due to a disease other than AMD
  • Pregnancy or lactation
  • Treatment of any systemic infection
  • Autofluorescence pattern marked at none, focal or patchy
  • Ocular surgery in the study eye in the previous 6 months.
  • Presence or history of choroidal neovascularization (wet AMD) in the study eye
  • Any inflammatory (autoimmune, uveitis) or neovascular (diabetic retinopathy) disease of the retina
  • Any history of glaucoma or disc cupping in the study eye
  • Any history of severe dry eye disease
  • High myopia > - 8D or high hyperopia > +8D in the study eye
  • Presence of life-threatening disease
  • Abnormal basal metabolic panel or liver function tests
  • Current alcohol or other substance abuse
  • Unwilling or unable to provide signed informed consent for any study procedures

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01093170

Layout table for location information
United States, Kentucky
University of Kentucky / Dept of Ophthalmology
Lexington, Kentucky, United States, 40536
Sponsors and Collaborators
Mark Kleinman
Layout table for investigator information
Principal Investigator: Jayakrishna Ambati, MD University of Kentucky
Layout table for additonal information
Responsible Party: Mark Kleinman, Sponsor/PI, University of Kentucky Identifier: NCT01093170    
Other Study ID Numbers: 144101a
First Posted: March 25, 2010    Key Record Dates
Last Update Posted: January 17, 2018
Last Verified: January 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Geographic Atrophy
Pathological Conditions, Anatomical
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases